Skip to content
Markets
This is research, not advice. We’re not SEBI-registered.

Bulk Drug and Formulation Stocks and Companies in India

No bulk drug and formulation has a 🤑 or 🚀 tag · 4 of 4 beat the NIFTY 500 over 3 years, or since listing for a newer company

By market cap🤑 Deep value (our tag): share price grew slower than profit and sales over 3 to 5 years, returns not falling🚀 Speeding up: profit and sales growth and the price all quickeningNo company carries either mark on this pageRank = our Deep value score: business 50 + speed-up 30 + lag 20
Share price, formulations index and NIFTY 5001Y to 10Y

Anlon Healthcare leads at +192%; 4 of 4 beat the NIFTY 500

No 🚀 or 🤑 company among those picked

Since 17 Nov 2023+170% formulations indexMedian company +100% · NIFTY 500 +34.8%
Median company +100%
1Valiant Laboratories+61.4%
2Alivus Life Sciences+133%
3Anlon Healthcare+192%
4Amanta Healthcare+67.6%
Median company +100%
1Valiant Laboratories+61.4%
2Alivus Life Sciences+133%
3Anlon Healthcare+192%
4Amanta Healthcare+67.6%
Formulations index, all 4 companies at equal weight: 1Y change, then growth a year1Y+82.4%3Y+39.2%/yr5Y+21.2%/yr10YToo short
Formulations index (equal weight)NIFTY 500Companies: colours as the chips aboveRanked by our score; bars show each company's price change, a later listing from its first close; dashed line: the median company

EPS growth, TTM1Y to 10Y

Alivus Life Sciences leads at +9.8% a year over 3 years; 1 of 1 grew

No 🚀 or 🤑 company among those picked

TTM, mostly to Sep 2026+9.8% a year, median EPS growth over 3 years4 companies, latest each
Last 12 monthsMedian +9.8%/yr
1Valiant Laboratoriesn/a+176%
2Alivus Life Sciences+9.8%/yr+26.1%
3Anlon Healthcaren/a−17.5%
4Amanta Healthcaren/a−7.3%
Last 12 monthsMedian +9.8%/yr
1Valiant Laboratoriesn/a+176%
2Alivus Life Sciences+9.8%/yr+26.1%
3Anlon Healthcaren/a−17.5%
4Amanta Healthcaren/a−7.3%
MedianNow, Sep 26+9.4%Mar 25+3.2%Sep 23Too shortSep 21Too short
Median of pickedLines: 3-quarter average (headline and bars: latest actual)Dotted: no figure that dateBars: latest TTM growth, ranked by our score. Right column: growth a year (3Y and longer)

Revenue growth, TTM1Y to 10Y

Anlon Healthcare leads at +15.9% a year over 3 years; 4 of 4 grew

No 🚀 or 🤑 company among those picked

TTM, mostly to Sep 2026+8.1% a year, median revenue growth over 3 years4 companies, latest each
Last 12 monthsMedian +8.1%/yr
1Valiant Laboratories+11.4%/yr+102%
2Alivus Life Sciences+4.7%/yr+8.1%
3Anlon Healthcare+15.9%/yr+26.9%
4Amanta Healthcare+3.6%/yr+9.9%
Last 12 monthsMedian +8.1%/yr
1Valiant Laboratories+11.4%/yr+102%
2Alivus Life Sciences+4.7%/yr+8.1%
3Anlon Healthcare+15.9%/yr+26.9%
4Amanta Healthcare+3.6%/yr+9.9%
MedianNow, Sep 26+18.4%Mar 25+1.4%Mar 23+15.1%Sep 21Too short
Median of pickedLines: 3-quarter average (headline and bars: latest actual)Dotted: no figure that dateBars: latest TTM growth, ranked by our score. Right column: growth a year (3Y and longer)

ROCE, TTM1Y to 10Y

Alivus Life Sciences leads at 26.4%; lowest Valiant Laboratories 0.8%

No 🚀 or 🤑 company among those picked

TTM, mostly to Sep 202614.0% median ROCE4 companies, latest each
Median 14.0%
1Valiant Laboratories0.8%
2Alivus Life Sciences26.4%
3Anlon Healthcare16.9%
4Amanta Healthcare11.2%
Median 14.0%
1Valiant Laboratories0.8%
2Alivus Life Sciences26.4%
3Anlon Healthcare16.9%
4Amanta Healthcare11.2%
MedianNow, Sep 2616.9%Mar 2519.9%Mar 2315.6%Sep 21Too short
Median of pickedLines: yearly figuresDotted: no figure that dateBars: latest TTM figure, ranked by our score

🤑 Deep value (our tag): share price grew slower than profit and sales over 3 to 5 years, returns not falling

🚀 Speeding up: profit and sales growth and the price all quickening

Rank = our Deep value score: business 50 + speed-up 30 + lag 20

Industry · 4 companies

There are 4 listed Bulk Drug and Formulation stocks in India: Alivus Life Sciences (₹17,670 crore), Anlon Healthcare (₹1,338 crore), Amanta Healthcare (₹863 crore) and Valiant Laboratories, at prices of 20 November 2026. 2 of the 4 companies we track are beating the Nifty 500 on share price over recent months.

Bulk Drug and Formulation: Alivus Life Sciences Ltd owns the largest revenue base; Valiant Laboratories Ltd has the fastest current growth.

The main question: the biggest companies are not always the ones changing the most.

Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.

How big is the Bulk Drug and Formulation sector?

There are 4 listed Bulk Drug and Formulation companies on this page, worth ₹20,400 cr together at prices of 20 November 2026. Alivus Life Sciences alone is ₹17,700 cr, about 87% of the total.

4Companies every listed company in this industry
₹20,400 crCombined market value all of them together
4/4Revenue growing revenue over the last 12 months up on a year earlier
2/4Beating NIFTY 500 pass the weekly momentum test: 5+ points ahead over 3 months, within 20% of the 52-week high
2 of 4 pass the weekly momentum test (5+ points ahead of the NIFTY 500 over 3 months, within 20% of the 52-week high)

Market values at prices of 20 November 2026.

What did Bulk Drug and Formulation managements say about July to September 2026?

1 of 2 Pharmaceuticals Bulk Drugs & Formulation companies held a results call for July to September 2026. Amanta Healthcare guided: Two-year aim 20%+ revenue yearly growth with 25%+ operating margin on operating leverage and mix.

Amanta Healthcare call 4 November 2026

“We are very, very happy to share with all of you that since 2016, which is almost 10 years, we must have marketed more than 35 crore bottles of Steriport, and we are yet to receive a single complaint of fungal contamination.”Bhavesh Patel

Guided: Two-year aim 20%+ revenue yearly growth with 25%+ operating margin on operating leverage and mix.

From the results calls for July to September 2026.

Is money moving into Bulk Drug and Formulation stocks? Who is adding capacity?

Big funds, foreign and Indian, kept their stake about the same over the last two quarters. Founders and promoters kept theirs about the same.

  • Spending on new plants and equipment was ₹707 crore in the last 12 months, 2% more than a year before.
  • Projects still being built grew 40% in a year.

Big funds = foreign and Indian institutions, change in their share of ownership across 4 Pharmaceuticals Bulk Drugs & Formulation companies, in percentage points.

Ownership and spending as of 10 October 2026.

Which are the biggest Bulk Drug and Formulation stocks in India?

The largest Bulk Drug and Formulation stocks in India by market value are Alivus Life Sciences (₹17,670 crore), Anlon Healthcare (₹1,338 crore) and Amanta Healthcare (₹863 crore), at prices of 20 Nov 2026.

Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 20 Nov 2026; the score list below uses the weekly figures.

Is there a Nifty Bulk Drug and Formulation index, and what is in it?

All 4 listed Indian Pharmaceuticals Bulk Drugs & Formulation companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Pharmaceuticals Bulk Drugs & Formulation index; the exchange publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. One large company cannot set the reading.

  1. Alivus Life Sciences Ltd₹17,700 cr
  2. Anlon Healthcare Ltd₹1,340 cr
  3. Amanta Healthcare Ltd₹863 cr
  4. Valiant Laboratories Ltd₹515 cr

How many Bulk Drug and Formulation companies are listed in India?

4 Bulk Drug and Formulation companies in the Pharmaceuticals Bulk Drugs & Formulation industry group have a page on Sector Alpha, and all 4 are listed below, largest first. The largest is Alivus Life Sciences (₹17,670 crore) and the smallest with a market value is Valiant Laboratories.

Every Pharmaceuticals Bulk Drugs & Formulation company with a page, largest first
CompanyMarket value
1. Alivus Life Sciences Ltd ALIVUS₹17,670 crore
2. Anlon Healthcare Ltd AHCL₹1,338 crore
3. Amanta Healthcare Ltd AMANTA₹863 crore
4. Valiant Laboratories Ltd VALIANTLAB₹515 crore

Download all 4 Bulk Drug and Formulation companies (CSV)

How have Bulk Drug and Formulation stocks moved against NIFTY 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 60% ahead of NIFTY 500. Earnings across its companies grew 11% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 16 weeks running.

Leader · ahead 16w ~

Price and the fundamentals both up. 2 of 4 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high).

Ahead of NIFTY 500 on the three-month view for 16 weeks running; 4 of the 4 companies in the industry index above their 200-day average (no change from four weeks earlier); 2 of those 4 pass the momentum test (1 fewer than four weeks earlier); earnings rising at 2 of the 4 that report earnings.

Ahead of NIFTY 500 for 16 weeks running and +83.4% over a year, with 3 → 2 of 4 stocks participating. Earnings mixed, 2 of 4 members have higher trailing twelve-month earnings than a year ago.

1Y

Pharmaceuticals Bulk Drugs & Formulation against NIFTY 500

Both lines start at 200 in the first week shown

  • Bulk Drug and Formulation 368
  • NIFTY 500 200
Pharmaceuticals Bulk Drugs & Formulation against NIFTY 500
Week endingBulk Drug and FormulationNIFTY 500
21 Nov 2025200200
28 Nov 2025195201
5 Dec 2025191200
12 Dec 2025187199
19 Dec 2025189199
26 Dec 2025194200
2 Jan 2026197203
9 Jan 2026189197
16 Jan 2026184197
23 Jan 2026173191
30 Jan 2026174194
6 Feb 2026178197
13 Feb 2026178196
20 Feb 2026175197
27 Feb 2026169195
6 Mar 2026169189
13 Mar 2026167180
20 Mar 2026176179
27 Mar 2026172177
3 Apr 2026178176
10 Apr 2026190188
17 Apr 2026211192
24 Apr 2026222190
1 May 2026214191
8 May 2026225194
15 May 2026214189
22 May 2026216190
29 May 2026215190
5 Jun 2026214189
12 Jun 2026223190
19 Jun 2026230195
26 Jun 2026234194
3 Jul 2026233196
10 Jul 2026236196
17 Jul 2026229196
24 Jul 2026225193
31 Jul 2026227197
7 Aug 2026238199
14 Aug 2026253198
21 Aug 2026277198
28 Aug 2026284198
4 Sep 2026292195
11 Sep 2026327192
18 Sep 2026338192
25 Sep 2026365190
2 Oct 2026372184
9 Oct 2026350184
16 Oct 2026354187
23 Oct 2026332180
30 Oct 2026344184
6 Nov 2026370197
13 Nov 2026368200

3Y

Pharmaceuticals Bulk Drugs & Formulation against NIFTY 500

Both lines start at 200 in the first week shown, every 2nd week shown

  • Bulk Drug and Formulation 353
  • NIFTY 500 269
Pharmaceuticals Bulk Drugs & Formulation against NIFTY 500
Week endingBulk Drug and FormulationNIFTY 500
24 Nov 2023200200
1 Dec 2023197205
15 Dec 2023193217
29 Dec 2023197220
12 Jan 2024210224
26 Jan 2024236220
9 Feb 2024234226
23 Feb 2024231230
8 Mar 2024209232
22 Mar 2024196227
5 Apr 2024217235
19 Apr 2024211231
3 May 2024211238
17 May 2024205239
31 May 2024199239
14 Jun 2024209252
28 Jun 2024205256
12 Jul 2024212262
26 Jul 2024203264
9 Aug 2024204260
23 Aug 2024203265
6 Sep 2024231266
20 Sep 2024223274
4 Oct 2024222267
18 Oct 2024216266
1 Nov 2024211259
15 Nov 2024209249
29 Nov 2024214257
13 Dec 2024209265
27 Dec 2024203254
10 Jan 2025200247
24 Jan 2025210242
7 Feb 2025219245
21 Feb 2025186235
7 Mar 2025186232
21 Mar 2025186241
4 Apr 2025183236
18 Apr 2025188246
2 May 2025203249
16 May 2025211259
30 May 2025201258
13 Jun 2025214260
27 Jun 2025209268
11 Jul 2025208264
25 Jul 2025199261
8 Aug 2025183254
22 Aug 2025187261
5 Sep 2025178259
19 Sep 2025209266
3 Oct 2025197261
17 Oct 2025190268
31 Oct 2025190269
14 Nov 2025193270
28 Nov 2025187271
12 Dec 2025179269
26 Dec 2025186270
9 Jan 2026181266
23 Jan 2026166257
6 Feb 2026171266
20 Feb 2026168265
6 Mar 2026162255
20 Mar 2026169242
3 Apr 2026170237
17 Apr 2026202259
1 May 2026205257
15 May 2026205255
29 May 2026205257
12 Jun 2026213256
26 Jun 2026224262
10 Jul 2026226265
24 Jul 2026215260
7 Aug 2026228269
21 Aug 2026265267
4 Sep 2026279264
18 Sep 2026323259
2 Oct 2026356248
16 Oct 2026339252
30 Oct 2026329248
13 Nov 2026353269

5Y

Pharmaceuticals Bulk Drugs & Formulation against NIFTY 500

Both lines start at 200 in the first week shown, every 4th week shown

  • Bulk Drug and Formulation 370
  • NIFTY 500 323
Pharmaceuticals Bulk Drugs & Formulation against NIFTY 500
Week endingBulk Drug and FormulationNIFTY 500
26 Nov 2021200200
17 Dec 2021194200
14 Jan 2022193214
11 Feb 2022174203
11 Mar 2022154194
8 Apr 2022162209
6 May 2022146192
3 Jun 2022140191
1 Jul 2022141182
29 Jul 2022148199
26 Aug 2022140206
23 Sep 2022131205
21 Oct 2022130205
18 Nov 2022135211
16 Dec 2022136213
13 Jan 2023132209
10 Feb 2023121204
10 Mar 2023125200
7 Apr 2023130201
5 May 2023165208
2 Jun 2023175215
30 Jun 2023182223
28 Jul 2023211230
25 Aug 2023200229
22 Sep 2023206235
20 Oct 2023211234
17 Nov 2023211239
15 Dec 2023203260
12 Jan 2024221269
9 Feb 2024246271
8 Mar 2024219278
5 Apr 2024227282
3 May 2024221285
31 May 2024209287
28 Jun 2024215307
26 Jul 2024213317
23 Aug 2024213318
20 Sep 2024234329
18 Oct 2024227319
15 Nov 2024220299
13 Dec 2024219318
10 Jan 2025210296
7 Feb 2025229294
7 Mar 2025195278
4 Apr 2025192283
2 May 2025213299
30 May 2025211310
27 Jun 2025219321
25 Jul 2025209313
22 Aug 2025196313
19 Sep 2025219319
17 Oct 2025200321
14 Nov 2025202324
12 Dec 2025188323
9 Jan 2026190319
6 Feb 2026179319
6 Mar 2026169306
3 Apr 2026179285
1 May 2026215308
29 May 2026216308
26 Jun 2026235314
24 Jul 2026226312
21 Aug 2026278320
18 Sep 2026339311
16 Oct 2026355303
13 Nov 2026370323

Earnings, each company rebased to 100, the sector takes the median

Latest quarter July to September 2026: 90.2, from 4 companies

Earnings, each company rebased to 100, the sector takes the median
QuarterMedian earnings index
Oct 2023100.0 (2 companies)
Jan 202452.9 (2 companies)
Apr 202446.9 (2 companies)
Jul 202444.4 (2 companies)
Oct 202446.4 (2 companies)
Jan 202591.1 (4 companies)
Apr 202585.2 (4 companies)
Jul 202596.1 (4 companies)
Oct 2025103.4 (4 companies)
Jan 202680.7 (4 companies)
Apr 202679.4 (4 companies)
Jul 202690.2 (4 companies)

Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 4 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Are Bulk Drug and Formulation stocks outperforming NIFTY 500?

Pharmaceuticals Bulk Drugs & Formulation has done better than the NIFTY 500 by 84.1% over the last 52 weeks. Over 13 weeks the gap is a lead of 39.1%. Amanta Healthcare Ltd is the strongest against the sector itself at +9.4%. Readings are as of 13 November 2026.

+39.1%Sector vs NIFTY 500 · 13 weeks
+84.1%Sector vs NIFTY 500 · 52 weeks
2 of 4Stocks leading NIFTY 500
2 of 4Stocks leading the sector

Relative-strength score for the industry: 52.7 as of 13 November 2026 (narrowing, rising).

What is the bottom line on Bulk Drug and Formulation stocks?

Pharmaceuticals Bulk Drugs & Formulation has done better than the NIFTY 500 by 84.1% over 52 weeks and by 39.1% over 13 weeks. 2 of 4 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 2 of the 3 with a long enough price history are ahead of the industry itself.

How does each Bulk Drug and Formulation stock score?

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

Growth & earnings · 35% Capital efficiency · 25% Valuation · 20% Relative strength · 20%

Anlon Healthcare Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 74% evidence confidence.

  1. 1Anlon Healthcare LtdAHCL · breaking out · favourable · 74% evidence65.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.3/35 · Revenue 26.9% · PAT 2.8% · OPM change −2.3 pp · 100% evidenceCapital efficiency 19.2/25 · ROCE 22.4% (year to Mar 2026) · OPM 23.9% · 100% evidenceValuation 10.0/20 · P/E 48.4× · PEG — · 0% evidenceRelative strength 17.0/20 · RS sector 9% · RS bench 57.6% · 1Y 62.3% · 70% evidence · 12 of 12 weeks aheadExact sum: 19.3 + 19.2 + 10 + 17 = 65.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Alivus Life Sciences LtdALIVUS · fading · mixed, leaning good · 97% evidence63.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.7/35 · Revenue 8.1% · PAT 26.2% · OPM change 9 pp · 100% evidenceCapital efficiency 23.0/25 · ROCE 23.8% (year to Mar 2026) · OPM 38.9% · 100% evidenceValuation 9.8/20 · P/E 26.3× · PEG 1.41 · 85% evidenceRelative strength 5.0/20 · RS sector −14.2% · RS bench 27.5% · 1Y 59% · 100% evidence · 11 of 12 weeks aheadExact sum: 25.7 + 23 + 9.8 + 5 = 63.5 · What this means: Earnings are strong; relative strength in its sector is −14.2% and the one-year return is 59%.
  3. 3Valiant Laboratories LtdVALIANTLAB · breaking out · mixed, leaning good · 65% evidence60.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 33.3/35 · Revenue 100% · PAT 100% · OPM change 4.3 pp · 100% evidenceCapital efficiency 4.8/25 · ROCE 0.6% (year to Mar 2026) · OPM 4.4% · 100% evidenceValuation 10.0/20 · P/E 31.9× · PEG — · 0% evidenceRelative strength 12.5/20 · RS sector — · RS bench 27.9% · 1Y — · 25% evidence · 7 of 7 weeks aheadExact sum: 33.3 + 4.8 + 10 + 12.5 = 60.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4Amanta Healthcare LtdAMANTA · leader · mixed, leaning good · 74% evidence60.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.2/35 · Revenue 9.9% · PAT 22.5% · OPM change 0 pp · 100% evidenceCapital efficiency 12.3/25 · ROCE 11.6% (year to Mar 2026) · OPM 20.7% · 100% evidenceValuation 10.0/20 · P/E 47.2× · PEG — · 0% evidenceRelative strength 17.0/20 · RS sector 9.4% · RS bench 59.8% · 1Y 90.6% · 70% evidence · 11 of 12 weeks aheadExact sum: 21.2 + 12.3 + 10 + 17 = 60.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
How this score is built, and what the marks mean

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

How have Bulk Drug and Formulation share prices moved?

Amanta Healthcare Ltd has the strongest one-year price move in Pharmaceuticals Bulk Drugs & Formulation at +90.6%. It also leads on relative strength against the NIFTY, at +59.8%. 4 of 4 companies we track are ahead of the index on that measure. Every line covers 314 weekly closes through 13 November 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Pharmaceuticals Bulk Drugs & Formulation itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

Biggest one-year moves

  1. 1Amanta Healthcare LtdAMANTA · ₹863 cr+90.6%1 year
  2. 2Anlon Healthcare LtdAHCL · ₹1,340 cr+62.3%1 year
  3. 3Alivus Life Sciences LtdALIVUS · ₹17,700 cr+59.0%1 year

Strongest against NIFTY 500

  1. 1Amanta Healthcare LtdAMANTA · ₹863 cr+59.8%vs NIFTY 500
  2. 2Anlon Healthcare LtdAHCL · ₹1,340 cr+57.6%vs NIFTY 500
  3. 3Valiant Laboratories LtdVALIANTLAB · ₹515 cr+27.9%vs NIFTY 500
  4. 4Alivus Life Sciences LtdALIVUS · ₹17,700 cr+27.5%vs NIFTY 500

Strongest against the sector itself

  1. 1Amanta Healthcare LtdAMANTA · ₹863 cr+9.4%vs sector
  2. 2Anlon Healthcare LtdAHCL · ₹1,340 cr+9.0%vs sector
  3. 3Alivus Life Sciences LtdALIVUS · ₹17,700 cr−14.2%vs sector

What is changing in Bulk Drug and Formulation stocks?

This is the written read behind the Pharmaceuticals Bulk Drugs & Formulation figures above: what is actually happening in the industry, in words, with the evidence each claim rests on. It is dated 19 Apr 2026, so the words are older than the numbers. 5 themes are live here.

The sector is in a transition phase where high-margin CDMO and specialty portfolios are successfully offsetting generic price erosion. While profitability is at record levels, the divergence in capex strategies and elevated working capital cycles suggest that execution on new capacity utilization will be the key differentiator in FY27.

The Pharmaceuticals Bulk Drugs & Formulation sector is witnessing a period of margin expansion, with constituents reporting EBITDA margins in the 36.4% to 37.3% range. This performance is underpinned by a transition from commodity APIs to value-added segments.

How old this read is: OLD: this read comes from our Pharmaceuticals Bulk Drugs & Formulation sector brief dated 19 Apr 2026, about 7 months ago. The page says so rather than dressing it up, and a fresh sector dive replaces it the day it runs.

What is live in this sector right now

Live theme, Severity, Evidence on file
Live themeSeverityEvidence on file
Anticipated 5% price erosion in the generic API business due to competitive intensity.Named for Alivus Life Sciencesmedium“On the overall growth, you can take about 5% price erosion, Tarang. The balance is the volume growth.” Mitigated by next-generation process improvements and higher-margin new launches.
Includes US tariff uncertainties and local environmental penalties.Named for Alivus Life Sciences, SUDEEPPHRMmedium“it became clear that only 50% of our U.S. business is subject to the announced tariff” SUDEEPPHRM passed on tariff impacts to 90% of customers; ALIVUS views its fine as a one-off.
China's elimination of VAT rebates on exports could increase global prices for competing products.Named for SUDEEPPHRMlow“China had announced the elimination of the VAT rebate. ... I think it's gone up maybe 15%-20%” Management views this as supporting the narrative for an ex-China supply chain.
Need for localized stocking to improve service levels in international markets.Named for SUDEEPPHRMlow“the company has recently commenced warehousing operations in USA and Europe to improve service level and responsiveness.” Commenced warehousing operations in the USA and Europe.
Double hit from Renminbi strengthening and Rupee weakening against the USD.Named for Alivus Life Scienceslow“Renminbi is strengthening against the dollar and then the Rupee is weakening against the dollar. So, we have a kind of a double hit.” 6-month contracts and a distributed supply base are in place.

Sources: our Pharmaceuticals Bulk Drugs & Formulation sector brief, 19 Apr 2026 · company earnings-call transcripts.

Which Bulk Drug and Formulation companies have the most revenue, and which grow fastest?

Alivus Life Sciences Ltd has the highest Revenue among the 4 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at ₹2,684 crore. Valiant Laboratories Ltd is next at ₹377 crore. Valiant Laboratories Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Alivus Life Sciences Ltd is the largest at ₹2,684 crore, 612.9% ahead of Valiant Laboratories Ltd. Valiant Laboratories Ltd's growth is capped at 100% on the scoring scale; the full change over the last 12 months is 102.4% from a ₹377 crore base, with 18 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

Alivus Life Sciences Ltd · ₹2,684 croreLeader
612.9% versus #2 · Valiant Laboratories LtdGap
8/8 recent comparable periodsPersistence
4/4 companies · 58 observationsCoverage

What this means: Alivus Life Sciences Ltd is the size to compare against; Valiant Laboratories Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Alivus Life Sciences Ltd's growth falls below Valiant Laboratories Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue · largest

  1. 1Alivus Life Sciences LtdALIVUS₹2,680 cr
  2. 2Valiant Laboratories LtdVALIANTLAB₹377 cr
  3. 3Amanta Healthcare LtdAMANTA₹303 cr
  4. 4Anlon Healthcare LtdAHCL₹182 cr

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue, every company
CompanyRevenueRevenue growthReported
Alivus Life Sciences Ltd ALIVUS₹682 cr16%Sep 2026
Valiant Laboratories Ltd VALIANTLAB₹117 cr153%Sep 2026
Amanta Healthcare Ltd AMANTA₹83.1 cr17%Sep 2026
Anlon Healthcare Ltd AHCL₹60.5 cr16%Sep 2026

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

What to watch

Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.

Which Bulk Drug and Formulation companies keep the most from each ₹100 of sales?

Alivus Life Sciences Ltd has the highest OPM among the 4 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at 38.9%. Anlon Healthcare Ltd is next at 23.9%. The same company also has the highest Margin change, at +9 percentage points. 4 of 4 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Alivus Life Sciences Ltd leads both opm at 38.9% and margin change at +9 percentage points.

Alivus Life Sciences Ltd · 38.9%Leader
62.8% versus #2 · Anlon Healthcare LtdGap
6/8 recent comparable periodsPersistence
4/4 companies · 58 observationsCoverage

What this means: Alivus Life Sciences Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM, by reported quarter

  • Alivus Life Sciences 39%
  • Anlon Healthcare 24%
  • Amanta Healthcare 21%
  • Valiant Laboratories 4.4%
OPM, by reported quarter
QuarterAlivus Life SciencesAnlon HealthcareAmanta HealthcareValiant Laboratories
Dec 202128%———
Mar 202228%———
Jun 202230%——8.4%
Sep 202228%——12%
Dec 202227%——14%
Mar 202333%——9.6%
Jun 202333%——7.0%
Sep 202328%——−2.3%
Dec 202330%——−16%
Mar 202426%——−15%
Jun 202427%18%20%−13%
Sep 202427%31%21%−31%
Dec 202430%6.2%22%1.8%
Mar 202531%35%26%6.6%
Jun 202529%19%23%5.1%
Sep 202530%26%21%0.2%
Dec 202534%35%21%−1.7%
Mar 202631%25%19%5.2%
Jun 202633%24%21%25%
Sep 202639%24%21%4.4%

Margin change, by reported quarter

  • Alivus Life Sciences +9.0 pp
  • Anlon Healthcare −2.3 pp
  • Amanta Healthcare +0.01 pp
  • Valiant Laboratories +4.3 pp
Margin change, by reported quarter
QuarterAlivus Life SciencesAnlon HealthcareAmanta HealthcareValiant Laboratories
Dec 2021−3.0 pp———
Mar 2022−8.7 pp———
Jun 2022−0.6 pp———
Sep 2022−1.6 pp———
Dec 2022−1.0 pp———
Mar 2023+5.3 pp———
Jun 2023+3.0 pp——−1.4 pp
Sep 2023−0.2 pp——−14.5 pp
Dec 2023+3.0 pp——−29.6 pp
Mar 2024−7.0 pp——−24.4 pp
Jun 2024−6.0 pp——−19.7 pp
Sep 2024−1.0 pp——−29.1 pp
Dec 20240.0 pp——+17.3 pp
Mar 2025+5.0 pp——+21.4 pp
Jun 2025+2.0 pp+0.6 pp+3.1 pp+17.8 pp
Sep 2025+3.0 pp−4.9 pp−0.1 pp+31.6 pp
Dec 2025+4.0 pp+28.3 pp−1.6 pp−3.5 pp
Mar 20260.0 pp−10.0 pp−6.9 pp−1.4 pp
Jun 2026+4.0 pp+5.3 pp−1.7 pp+20.3 pp
Sep 2026+9.0 pp−2.3 pp+0.0 pp+4.3 pp

4 of 4 companies report OPM, 4 of 4 margin change.

OPM · highest

Margin change · fastest expanders

  1. 1Alivus Life Sciences LtdALIVUS+9.0 pp
  2. 2Valiant Laboratories LtdVALIANTLAB+4.3 pp
  3. 3Amanta Healthcare LtdAMANTA+0.0 pp
  4. 4Anlon Healthcare LtdAHCL−2.3 pp

All-company data · latest reported quarter

Operating margin, every company
CompanyOPMMargin changeReported
Alivus Life Sciences Ltd ALIVUS39%+9.0 ppSep 2026
Anlon Healthcare Ltd AHCL24%−2.3 ppSep 2026
Amanta Healthcare Ltd AMANTA21%+0.0 ppSep 2026
Valiant Laboratories Ltd VALIANTLAB4.4%+4.3 ppSep 2026

What to watch

Watch whether the next two comparable periods confirm the current margin change rather than reversing it.

Which Bulk Drug and Formulation companies earn the most profit?

Alivus Life Sciences Ltd has the highest Net profit among the 4 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at ₹670 crore. Anlon Healthcare Ltd is next at ₹28 crore. Valiant Laboratories Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Alivus Life Sciences Ltd earns the most, ₹670 crore of profit over the last 12 months, 24.1× the profit of Anlon Healthcare Ltd. Valiant Laboratories Ltd shows at least 100% on the scoring scale (219.7% in full) growth from a profit base of ₹16 crore. A fast rate from a small base matters less than a large profit that keeps coming.

Alivus Life Sciences Ltd · ₹670 croreLeader
24.1× versus #2 · Anlon Healthcare LtdGap
8/8 recent comparable periodsPersistence
4/4 companies · 58 observationsCoverage

What this means: Alivus Life Sciences Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit · largest

  1. 1Alivus Life Sciences LtdALIVUS₹670 cr
  2. 2Anlon Healthcare LtdAHCL₹27.8 cr
  3. 3Amanta Healthcare LtdAMANTA₹18.3 cr
  4. 4Valiant Laboratories LtdVALIANTLAB₹16.2 cr

Profit growth · fastest growers

All-company data · latest reported quarter

Net profit, every company
CompanyNet profitProfit growthReported
Alivus Life Sciences Ltd ALIVUS₹197 cr52%Sep 2026
Anlon Healthcare Ltd AHCL₹8.1 cr−14%Sep 2026
Amanta Healthcare Ltd AMANTA₹4.9 cr302%Sep 2026
Valiant Laboratories Ltd VALIANTLAB₹0.4 cr105%Sep 2026

What to watch

Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.

Which Bulk Drug and Formulation companies earn the best return on capital?

Alivus Life Sciences Ltd has the highest ROCE among the 4 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at 23.8%. Anlon Healthcare Ltd is next at 22.4%. Anlon Healthcare Ltd has the highest ROCE change at +6.9 percentage points, so level and change sit with different companies. Its ROCE series carries 16 reported observations across the 20-quarter window.

What the numbers say: Alivus Life Sciences Ltd leads ROCE at 23.8%, 1.4 percentage points above Anlon Healthcare Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

Alivus Life Sciences Ltd · 23.8%Leader
6.3% versus #2 · Anlon Healthcare LtdGap
4/8 recent comparable periodsPersistence
4/4 companies · 46 observationsCoverage

What this means: Alivus Life Sciences Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

ROCE · highest

ROCE change · fastest improvers

All-company data · latest reported quarter

Return on capital, every company
CompanyROCEROCE changeReported
Alivus Life Sciences Ltd ALIVUS22%+0.9 ppSep 2026
Anlon Healthcare Ltd AHCL22%+6.9 ppSep 2026
Amanta Healthcare Ltd AMANTA14%+1.5 ppSep 2026
Valiant Laboratories Ltd VALIANTLAB7.7%+5.8 ppSep 2026

What to watch

Watch whether the next two comparable periods confirm the current roce change rather than reversing it.

How are Bulk Drug and Formulation stocks valued against growth and quality?

Alivus Life Sciences Ltd has the lowest PEG among the 4 Pharmaceuticals Bulk Drugs & Formulation companies compared here, at 1.41×. The same company also has the lowest P/E, at 26.3×. 1 of 4 companies report a comparable reading, the latest through Sep 2026. Its PEG series carries 7 reported observations across the 20-quarter window.

What the numbers say: That would need today's multiple, the company's own history and steady growth to agree.

Alivus Life Sciences Ltd · 1.41×Leader
Not enough peersGap
0/8 recent comparable periodsPersistence
1/4 companies · 7 observationsCoverage

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison

PEG, by reported quarter

PEG, by reported quarter
QuarterAlivus Life Sciences
Dec 2021—
Mar 2022—
Jun 2022—
Sep 2022—
Dec 2022—
Mar 2023—
Jun 20231.3
Sep 20231.0
Dec 2023—
Mar 2024—
Jun 2024—
Sep 2024—
Dec 2024—
Mar 2025—
Jun 2025—
Sep 20252.1
Dec 20250.8
Mar 20260.8
Jun 20261.2
Sep 20261.1

P/E, by reported quarter

P/E, by reported quarter
QuarterAlivus Life Sciences
Dec 202122.0×
Mar 202214.2×
Jun 202212.9×
Sep 202211.1×
Dec 202212.3×
Mar 202311.5×
Jun 202314.9×
Sep 202315.3×
Dec 202315.9×
Mar 202418.3×
Jun 202422.6×
Sep 202428.2×
Dec 202428.6×
Mar 202530.0×
Jun 202525.3×
Sep 202523.2×
Dec 202521.0×
Mar 202621.4×
Jun 202623.3×
Sep 202626.5×

1 of 4 companies report PEG, 4 of 4 P/E.

PEG · lowest PEG

P/E · lowest P/E

All-company data · latest reported quarter

Valuation, every company
CompanyPEGP/EReported
Alivus Life Sciences Ltd ALIVUS1.126.5×Sep 2026
Anlon Healthcare Ltd AHCL—63.2×Sep 2026
Amanta Healthcare Ltd AMANTA—48.2×Sep 2026
Valiant Laboratories Ltd VALIANTLAB—40.7×Sep 2026

What to watch

Watch whether the next two comparable periods confirm the current p/e rather than reversing it.

Which stock lists do Bulk Drug and Formulation companies appear on?

Pharmaceuticals Bulk Drugs & Formulation companies show up on 6 of our India lists. The most are on the pharma stocks list (4 companies).

What can make this comparison misleading?

This Pharmaceuticals Bulk Drugs & Formulation comparison names 5 specific ways its own evidence can mislead, all listed below. All 4 companies here report on comparable dates, so no rank carries a stale marker. 1 of the 5 ranked sections has fewer than three usable current readings. A high growth rate can still come from a very small starting figure.

Keep these limits visible

  • A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
  • The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
  • Thin comparisons: Valuation have fewer than three usable current readings.

How was this comparison built?

This comparison is built from the reported filings of 4 Pharmaceuticals Bulk Drugs & Formulation companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 13 November 2026.

FundamentalsThrough Sep 2026 · up to 20 quarters per company
Market dataThrough 13 November 2026 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and old evidence lowers confidence and pulls the 0 to 100 score toward the middle.
Source standing4 cross-checked · 0 unverified · 0 withheld, of 4 graded companies.

Every company's second-feed figures reconcile against the primary source on overlapping reported periods, so nothing here is unverified or withheld.

How a second data feed is admitted, and what happens when it disagrees

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree, the figures are simply used. Where there is too little shared history to compare, the figures are still drawn, they are the only evidence there is, and marked unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.

What else do people ask about Bulk Drug and Formulation stocks?

These 23 answers restate the Pharmaceuticals Bulk Drugs & Formulation comparison above in question form. Every one is computed from the same 4 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 13 November 2026. Nothing here is estimated, and none of it is a recommendation.

Is the Bulk Drug and Formulation sector outperforming NIFTY 500?

Pharmaceuticals Bulk Drugs & Formulation has done better than the NIFTY 500 by 84.1% over 52 weeks and by 39.1% over 13 weeks.

2 of 4 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 2 of the 3 with a long enough price history are ahead of the industry itself.

Which Bulk Drug and Formulation company is largest by revenue?

Alivus Life Sciences Ltd leads with revenue of ₹2,684 crore, based on 4 of 4 comparable companies through Sep 2026.

Which Bulk Drug and Formulation company is growing fastest?

Valiant Laboratories Ltd has the fastest current revenue growth at 100%, across 4 of 4 comparable companies.

Which Bulk Drug and Formulation company has the strongest 4-Factor Sector Score?

Anlon Healthcare Ltd ranks first at 65.5 out of 100, with 74% of the evidence available. The score ranks published data; it is not a recommendation.

Which Bulk Drug and Formulation company has the lowest comparable PEG?

Alivus Life Sciences Ltd has the lowest comparable PEG at 1.41, among 1 of 4 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Bulk Drug and Formulation comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.

Is there a Nifty Bulk Drug and Formulation index?

The exchange runs Nifty indices for several broad sectors, such as Nifty Bank, Nifty IT and Nifty Pharma, but not for every smaller group on this site.

Whether or not an official Nifty index covers Pharmaceuticals Bulk Drugs & Formulation, this page builds its own equal-weight basket of 4 listed Pharmaceuticals Bulk Drugs & Formulation companies: one company, one vote, whatever its size, so no single large company dominates. Figures are as of Sep 2026.

Which are the best Bulk Drug and Formulation stocks in India?

Ranked by this page's four-factor score, Anlon Healthcare Ltd comes first among 4 listed Pharmaceuticals Bulk Drugs & Formulation companies, followed by Alivus Life Sciences Ltd. That is a ranking of published data (earnings, quality, valuation and share-price behaviour as of Sep 2026), not a recommendation.

How many Bulk Drug and Formulation stocks are listed in India?

This comparison covers 4 listed Pharmaceuticals Bulk Drugs & Formulation companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Sep 2026.

Which Bulk Drug and Formulation company is the biggest?

Alivus Life Sciences Ltd is the largest, with revenue of ₹2,684 crore over the last 12 months, ahead of Valiant Laboratories Ltd at ₹377 crore. That covers 4 of 4 companies with comparable reporting through Sep 2026.

Which Bulk Drug and Formulation company has the best profit margins?

Alivus Life Sciences Ltd has the highest operating margin at 38.9%, from 4 of 4 comparable companies. Alivus Life Sciences Ltd shows the biggest recent improvement, at +9 percentage points. A high margin matters most when it is steady or rising, not when it is at a peak.

Which Bulk Drug and Formulation company makes the most profit?

Alivus Life Sciences Ltd earns the most, at ₹670 crore of net profit over the last 12 months, from 4 of 4 comparable companies.

Valiant Laboratories Ltd has the fastest profit growth at the 100% cap of the scoring scale, though growth off a small or recovering profit base overstates how much has actually changed.

Which Bulk Drug and Formulation company earns the highest return on capital?

Alivus Life Sciences Ltd leads on return on capital employed at 23.8%, across 4 of 4 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.

Which Bulk Drug and Formulation stock has the lowest PEG ratio?

On PEG (where a lower number means a lower price for what the company earns), Alivus Life Sciences Ltd has the lowest at 1.41×.

Only 1 of 4 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a ranking of the whole industry. A low multiple is a reason to look closer at the business, not a conclusion on its own.

Is the Bulk Drug and Formulation sector beating the market?

Pharmaceuticals Bulk Drugs & Formulation has done better than the NIFTY 500 by 84.1% over the last 52 weeks and by 39.1% over 13 weeks, measured on an equal-weight index of its current members.

Inside the sector, 2 of the 4 companies we track are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Bulk Drug and Formulation stock has the strongest price momentum?

Amanta Healthcare Ltd has the strongest relative strength against the NIFTY 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.

Which Bulk Drug and Formulation company has the highest 4-Factor score?

Anlon Healthcare Ltd scores 65.5 out of 100, with 74% of the evidence available, from 19.3 points on growth and earnings, 19.2 on capital efficiency, 10 on valuation and 17 on relative strength. It ranks published data only; management quality, upcoming events and risks are not part of the score.

How many Bulk Drug and Formulation companies does this comparison cover, and over what period?

This comparison covers 4 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.

What is the total market cap of the Bulk Drug and Formulation sector?

The 4 Pharmaceuticals Bulk Drugs & Formulation companies on this page carry ₹20,386 crore of combined market value. Alivus Life Sciences Ltd is the largest at ₹17,670 crore, about 87% of the sector's total on its own. Market value moves with price, so this reading is dated 13 November 2026.

How is the Bulk Drug and Formulation sector performing?

2 of the 4 Pharmaceuticals Bulk Drugs & Formulation companies we track are doing better than the NIFTY 500 on relative strength (how a share price has done against the index over recent months).

The sector itself is 84.1% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.

Is this advice?

No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.

More lists

Every Sector Alpha list, grouped

Every India sector against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 13 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.